EUVIMEDScopri EUVIMED
CrossrefScheda informativa

Graph_RG: Dominating CASP16 's Small Molecule Affinity Prediction Subcategory—A Pose‐Free Framework for Billion‐Scale Virtual Screening

Haiping Zhang

Proteins: Structure, Function, and Bioinformatics · 2026-01 · 94 (1) · 286-294

DOI: 10.1002/prot.70010 ↗
AbstractDati bibliografici

Abstract

ABSTRACT Protein–ligand interaction prediction is pivotal in early‐stage drug development, enabling large‐scale virtual screening, drug optimization, and reverse target searching. In this work, we present Graph_RG, our top‐performing model in the CASP16 small molecule track's protein–ligand affinity prediction category, achieving a N‐weighted Kendall's Tau of 0.42—significantly outperforming other submissions (second‐best: 0.36). Beyond accuracy, Graph_RG is noncomplex dependent, hence exhibits exceptional computational efficiency, operating > 100 000× faster than conformation‐search dependent prediction methods, thus enabling billion‐ to 10‐billion‐scale screening on standard servers. We further discuss the potential improvements for Graph_RG, including dataset optimization, atomic vector representation enhancements, and model architecture upgrades. We also introduce the potential broader applications in large‐scale drug screening, reverse target identification, and GPCR‐specific drug discovery. We also point out the development of an interactive web platform hosting Graph_RG and its derivative models to enhance accessibility. By integrating community feedback and iterative model refinement, this initiative bridges the gap between AI‐driven predictions and practical drug discovery, fostering advancements in both computational methodologies and biomedical applications.

Conoscenze adatte al tuo lavoro.

Dall’inizio gratuito alla ricerca bibliografica personale, fino alla Research Suite completa.

Visualizza tariffe →

Sono inclusi tutti i testi integrali degli editori?

No. Citazioni, abstract e testi integrali sono contenuti diversi. La disponibilità dipende dalla fonte, dall’accesso aperto e dalle licenze esistenti. Un piano EUVIMED non sostituisce diritti aggiuntivi degli editori.

Visualizza tariffe →